GlycoErase™ ALG9 Knockout Human Bladder Cancer Cell 5637

human bladder bancer bell line 5637 with ablated ALG9 expression provides a valuable tool for the examination of lipid-linked oligosaccharide assembly aberrations within the context of bladder carcinoma; the absence of functional ALG9 perturbs the N-glycosylation machinery, prompting researchers to explore the associations between N-glycosylation irregularities and various facets of bladder cancer, including its development, advancement, metastatic potential, and to investigate therapeutic strategies centered on ALG9.

KO Cell Lines

Human

Epithelial-like, adherent

1:3~1:6

5637

Bladder Urothelial Carcinoma

Bladder/Urinary Tract

>90%

The sterility test indicated an absence of microbial growth.

STR identification

Negative

Negative for HIV, HBV and HCV.

We conduct cell genetic stability studies in full compliance with ICH guidelines. Our expertise enables us to design and execute a comprehensive testing program tailored to your specific needs and regulatory requirements.

PCR, Sanger Sequencing

FBS & Penicillin/Streptomycin & RPMI

Functional assay

1 M cells/vial*2

Frozen

Dry ice

Made to order

Upon receipt, this product must be immediately transferred from dry ice to liquid nitrogen (-150°C to -190°C) and stored in a liquid nitrogen tank. Cell viability is critically dependent on proper handling. We cannot guarantee viability if these instructions are not strictly adhered to.

This product is provided for research only, not suitable for human or animal use. Due to the inherent limitations of infectious agent testing, investigators must exercise extreme caution when handling cells provided by Creative Biolabs, treating all cells as potentially biohazardous.

ALG9

ALG9 alpha-1,2-mannosyltransferase

DIBD1

11q23.1

Facilitates lipid-linked oligosaccharide assembly; mutations lead to CDG II (congenital disorder of glycosylation type II); multiple transcript variants (different isoforms) may influence enzyme specificity.